Edison Investment Research - Pacific Edge Ltd (PEB) Pacific Edge - Anticipating commercial growth

Report

Edison Investment Research

Maxim Jacobs

Pacific Edge - Anticipating commercial growth

Pacific Edge continues to make progress commercialising its suite of bladder cancer diagnostics products, with three tests currently available in the US market. An uplift in sales is expected as TRICARE and the Veterans Administration (VA) are under contract, although the exact timing of a sales ramp is unknown. In addition, the companyâ€™s discussions with Kaiser Permanente are nearing a final decision and progress has been made with achieving inclusion in the local coverage determination (LCD) by the US Centers for Medicare and Medicaid Services (CMS).

09/01/2018 12 EN

Underlying

Pacific Edge Ltd

Pacific Edge is engaged in the biotechnology research, development and the commercialization of methods of early detection and treatment of cancers and other genetics diseases.

See profile

NZPEBE0002S1 NZX New Zealand

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Analysts

Maxim Jacobs

Other Reports on these Companies

SmartInsider

Pacific Edge Limited: 1 director

A director at Pacific Edge Limited bought 397,942 shares at 0.136NZD and the significance rating of the trade was 57/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showing Close periods where trading activity is restricted under listing rules. The names ...

Free Trial

August 3, 2023 August 3, 2023 1 EN

TheScreener

Increased risk weighs on PACIFIC EDGE, penalising its rating down to Negative

The independent financial analyst theScreener just lowered the general evaluation of PACIFIC EDGE (NZ), active in the Biotechnology industry. As regards its fundamental valuation, the title still shows 0 out of 4 possible stars. Its market behaviour, however, has slightly deteriorated and will be qualified as risky moving forward. theScreener considers that these new qualifications justify an overall rating downgrade to Negative. As of the analysis date February 8, 2022, the closing price was NZD 1.10 and its target price was estimated at NZD 0.99.

Free Trial

February 9, 2022 February 9, 2022 1 EN

Edison Investment Research

Pacific Edge - Termination of coverage

Edison Investment Research is terminating coverage on Kcell Joint Stock Company (KCEL), Locate Bio, Pacific Edge (PEB), Tungsten Corporation (TUNG) and VEF (VEMF). Please note you should no longer rely on any previous research or estimates for these companies. All forecasts should now be considered redundant. Previously published reports can still be accessed via our website.

July 27, 2021 July 27, 2021 1 EN

Regional REIT - Q124 DPS unchanged ahead of refinancing

For Q124, Regional REIT (RGL) has maintained the rate of quarterly DPS at 1.2p. We expect DPS for the year will partly depend on RGL’s chosen re-financing route. Meanwhile, RGL’s asset disposal programme continues to progress. Portfolio EPC ratings have continued to show good improvement and, adjusted for disposals, rent roll and occupancy were robust. We have made no changes to our forecasts.

3h / 31m 3h / 31m 1 EN

Fiona Orford-Williams

Fiona Orford-Williams

4imprint Group - Solid start to the year

4imprint’s AGM trading update indicates a solid start to the year against a challenging market backdrop, with full-year expectations (and therefore our forecasts) unchanged. Group revenue growth of 6% over the prior year for the four months to end April is clearly ahead of the North American market, where Q124 industry revenue indications range from broadly flat to a small decline, indicating that the group is continuing to build market share. 4imprint is the largest distributor in North America, yet still only has a market share of around 5%, giving plenty of further runway for growth. CFO Da...

5h / 53m 5h / 53m 1 EN

Toby Thorrington

Toby Thorrington

Dowlais Group - Margin expansion despite mixed auto markets

Dowlais Group’s traditional automotive and powder metallurgy operations continue to outperform the market, albeit the slowdown in EV adoption has affected ePowertrain, leading to a marginal reduction in expectations. However, the key remains further progress in operating margins (6.1% in the period, up 30bp) on the journey to c 10%. This margin expansion should drive earnings momentum and subsequently share price performance.

6h / 3m 6h / 3m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Pacific Edge - Anticipating commercial growth

Pacific Edge Limited: 1 director

Increased risk weighs on PACIFIC EDGE, penalising its rating down to Negative

Pacific Edge - Termination of coverage

Regional REIT - Q124 DPS unchanged ahead of refinancing

4imprint Group - Solid start to the year

Dowlais Group - Margin expansion despite mixed auto markets

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe